A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.
PHASE2CompletedINTERVENTIONAL
Enrollment
252
Participants
Timeline
Start Date
April 30, 2001
Study Completion Date
July 31, 2003
Conditions
Leukemia, Nonlymphocytic, Acute
Interventions
DRUG
tipifarnib (R115777)
All Listed Sponsors
lead
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
NCT00354146 - A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia. | Biotech Hunter | Biotech Hunter